Avital Lev

发表

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

W. El-Deiry, D. Dicker, X. Tian, 2021, Neoplasia.

A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53

W. El-Deiry, J. Santiago, D. Dicker, 2021, bioRxiv.

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53

W. El-Deiry, J. Santiago, D. Dicker, 2021, eLife.

P53-independent restoration of p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

W. El-Deiry, D. Dicker, X. Tian, 2020, bioRxiv.

From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer-selective Pathways

W. El-Deiry, Amriti R Lulla, Avital Lev, 2018, Early Drug Development.

Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes

Avital Lev, Y. Reiter, K. Oved, 2005, Cancer Immunology, Immunotherapy.

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations

Roland L. Dunbrack, W. El-Deiry, J. Swensen, 2017, Oncotarget.

Discovery and clinical introduction of first-in-class imipridone ONC201

Neel S. Madhukar, Michael L. Wang, O. Elemento, 2016, Oncotarget.

Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo

Avital Lev, Y. Reiter, D. Zehn, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Melanoma Differentiation Antigen TCR-Like Specificity Directed Toward a Using a Recombinant Antibody with Selective Targeting of Melanoma and APCs

Avital Lev, Y. Reiter, I. Benhar, 2003 .

Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen 1

Avital Lev, Y. Reiter, I. Benhar, 2003, The Journal of Immunology.

Recruitment of CTL Activity by Tumor-Specific Antibody-Mediated Targeting of Single-Chain Class I MHC-Peptide Complexes1

Avital Lev, Y. Reiter, Hila K Novak, 2002, The Journal of Immunology.

Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity

Avital Lev, H. Hoogenboom, P. Chames, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Immunotoxins and Recombinant Immunotoxins in Cancer Therapy

Avital Lev, Y. Reiter, 2006 .

Recombinant antibodies with MHC‐restricted, peptide‐specific, T‐cell receptor‐like specificity: new tools to study antigen presentation and TCR–peptide–MHC interactions

Avital Lev, Y. Reiter, C. Cohen, 2003, Journal of molecular recognition : JMR.

Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.

K. Skorecki, Avital Lev, M. Tzukerman, 2002, Cancer research.

Isolation and Characterization of Human Recombinant Antibodies Endowed with the Antigen-specific , Major Histocompatibility Complex-restricted Specificity of T Cells Directed toward the Widely Expressed Tumor T-cell Epitopes of the Telomerase Catalytic Subunit 1

K. Skorecki, Avital Lev, M. Tzukerman, 2002 .

Vascular Endothelial Cells Have Impaired Capacity to Present Immunodominant, Antigenic Peptides: A Mechanism of Cell Type-Specific Immune Escape1

Avital Lev, Y. Reiter, B. Biedermann, 2005, The Journal of Immunology.

Type-Specific Immune Escape Antigenic Peptides : A Mechanism of Cell Capacity to Present Immunodominant , Vascular Endothelial Cells Have Impaired

Avital Lev, Y. Reiter, B. Biedermann, 2005 .

Structural Features on Peptide / HLA-A 2 and T Cell Receptors Recognize Nonidentical Tax and M 1 Peptide / HLA-A 2-Specific Fabs

Avital Lev, Y. Reiter, W. Biddison, 2003 .

ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer

W. El-Deiry, D. Dicker, Amriti R Lulla, 2018, Molecular Cancer Research.

Correction: Efficient Cross-Priming of Antiviral CD8+ T Cells by Antigen Donor Cells Is GRP94 Independent

J. Yewdell, J. Bennink, C. Nicchitta, 2010, The Journal of Immunology.

Efficient Cross-Priming of Antiviral CD8+ T Cells by Antigen Donor Cells Is GRP94 Independent1

J. Yewdell, J. Bennink, C. Nicchitta, 2009, The Journal of Immunology.

Is GRP94 Independent T Cells by Antigen Donor Cells + CD8Cross-Priming of Antiviral

J. Yewdell, J. Bennink, C. Nicchitta, 2009 .

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic

W. El-Deiry, D. Dicker, Avital Lev, 2020, Oncotarget.

The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation.

J. Yewdell, J. Bennink, L. Neckers, 2008, Immunity.

Viral infection modulates Qa-1b in infected and bystander cells to properly direct NK cell killing

Avital Lev, L. Sigal, C. Knudson, 2021, The Journal of experimental medicine.

Host ER–parasitophorous vacuole interaction provides a route of entry for antigen cross-presentation in Toxoplasma gondii–infected dendritic cells

I. Coppens, A. Sher, R. Goldszmid, 2009, The Journal of experimental medicine.

Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures

Luigi Grasso, W. El-Deiry, Avital Lev, 2017, Oncotarget.

miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells.

Yan Zhou, M. Einarson, W. El-Deiry, 2017, Cancer research.

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Yan Zhou, C. Benes, W. El-Deiry, 2017, Oncotarget.

Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer

W. El-Deiry, D. Dicker, Amriti R Lulla, 2017, Cancer biology & therapy.

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90

W. El-Deiry, D. Dicker, Avital Lev, 2021, Scientific Reports.

HIF1α inhibition by dual targeting of CDK4/6 and HSP90 reduces cancer cell viability including Rb-deficient cells

W. El-Deiry, D. Dicker, Avital Lev, 2020, bioRxiv.

Migratory Dendritic Cells, Group 1 Innate Lymphoid Cells, and Inflammatory Monocytes Collaborate to Recruit NK Cells to the Virus-Infected Lymph Node.

Avital Lev, Daniel Rubio, Ren-Huan Xu, 2018, Cell reports.

Getting in front and behind the enemy lines to counter virus infection.

Avital Lev, L. Sigal, 2013, Cell host & microbe.

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors

Neel S. Madhukar, O. Elemento, U. McDermott, 2017, PloS one.

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

C. Benes, W. El-Deiry, Amriti R Lulla, 2017, Cell cycle.

Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice

Avital Lev, E. Vadai, Y. Reiter, 2006, Cancer Immunology, Immunotherapy.

Self-reporting peptides illuminate the MHC groove.

J. Yewdell, Avital Lev, 2007, Nature chemical biology.

Tax and M1 Peptide/HLA-A2-Specific Fabs and T Cell Receptors Recognize Nonidentical Structural Features on Peptide/HLA-A2 Complexes 1

Avital Lev, Y. Reiter, W. Biddison, 2003, The Journal of Immunology.

Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action

J. Yewdell, J. Bennink, P. van Endert, 2010, Proceedings of the National Academy of Sciences.

Cutting Edge: MHC Class I–Ly49 Interaction Regulates Neuronal Function

J. Yewdell, J. Bennink, G. Brooker, 2008, The Journal of Immunology.

Abstract 258: Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic

W. El-Deiry, D. Dicker, Avital Lev, 2019, Experimental and Molecular Therapeutics.

miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.

Yan Zhou, W. El-Deiry, D. Dicker, 2022, American journal of cancer research.

Memory CD8⁺ T cells can outsource IFN-γ production but not cytolytic killing for antiviral protection.

Avital Lev, Daniel Rubio, Ren-Huan Xu, 2013, Cell host & microbe.

The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation.

J. Yewdell, J. Bennink, L. Neckers, 2008, Immunity.

This information is current as Regulates Neuronal Function Ly 49 Interaction − Cutting Edge : MHC Class

J. Yewdell, J. Bennink, Avital Lev, 2008 .